An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
Individuals who identify as sexual or gender minorities (SGM) appear to be at a higher risk of experiencing subjective cognitive decline (SCD) than individuals who identify as cisgender and heterosexual, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
The use of sleep medications may be associated with the risk of dementia or Alzheimer’s disease (AD) in older adults, according to two studies presented at the recent Alzheimer’s Association International Conference (AAIC 2019).
Multisensory dysfunction is tied to an increased risk of developing dementia or Alzheimer’s disease (AD) in older adults, thus underlining the importance of sensory evaluation in this patient subgroup and among those at risk of developing neurodegenerative illnesses, according to studies presented at AAIC 2019.
Biomarkers in the blood may present a new opportunity for developing a simple, noninvasive, and inexpensive screening test for Alzheimer’s disease (AD), according to studies presented at the Alzheimer's Association International Conference (AAIC) 2019.
Sex-specific differences in the way brain regions are connected may influence how tau propagates through the brain and thus, differences in the risk of Alzheimer’s disease between men and women; while participating in the workforce may help stave cognitive decline in women, suggest studies presented at AAIC 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.